The significance of angiogenesis in Hodgkin's lymphoma (HL) is not well defined. The aim of this study was to evaluate various morphometric characteristics of microvessels in lymph node sections of 286 patients with HL at diagnosis and investigate their relationship with clinicopathologic parameters and prognosis. Microvessel density (MVD), total vascular area (TVA) and several size-and shape-related microvascular parameters were quantitated -after anti-CD34 immunohistochemical staining -in the region of most intense vascularization, using image analysis. An increase in microvessel caliber parameters (area, perimeter, major and minor axis length) and a decrease in MVD were noted with increasing stage. An inverse relationship was recorded between MVD and the number of involved sites (NIS) and LDH. In univariate analysis, overall disease-specific survival was adversely affected by MVD and TVA, whereas inferior failure-free survival (FFS) was associated with the presence of more flattened vessel sections. Multivariate analysis disclosed that the extent of angiogenesis (MVD/ TVA), age and the NIS independently affected overall survival. Accordingly, FFS was independently linked to the shape of microvessels and albumin levels or the NIS. In conclusion, our data support the view that angiogenesis in HL provides independent prognostic information, requiring the concomitant evaluation of quantitative and qualitative aspects of microvascular network.
Introduction
The natural course of Hodgkin's lymphoma (HL) has been tremendously altered by treatment modalities applied during the last two decades. However, cure remains elusive for as many as 5-15% of early and 20-40% of advanced stage patients who progress during first-line therapy or relapse following an initial remission. [1] [2] [3] [4] Gaining insight into the biology of HL is imperative to the pretreatment identification of patients prone to treatment failure.
Angiogenesis is an integral component of the viability of all tumor types, reflecting the inviolable demand of a growing tumor for sufficient levels of nutrients and oxygen exchange. 5 A plethora of investigations support the intuitive notion that solid tumors progress in concert with an induction of neovascular response (for a review see Hlatky et al 6 ) . Evidence of the importance of angiogenesis in hematologic malignancies is rapidly accruing, indirectly implicating bone marrow angiogenesis in the pathophysiology and course of acute leukemias, 7 chronic myeloid and lymphoid leukemias, [8] [9] [10] myelodysplastic syndromes 11 and multiple myeloma. 12, 13 In non-Hodgkin's lymphomas (NHL) and B chronic lymphocytic leukemia, microvessel counts correlate with histologic grade and clinical stage, respectively. 9,14-17 A couple of reports, though, have disputed such a relationship. 18, 19 Furthermore, increased pretreatment serum levels of potent angiogenic molecules, notably vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), have been implicated in the prognosis of patients with malignant lymphomas. 20 Published information regarding angiogenesis in HL is limited to two recent reports focusing on the expression of VEGF by Reed-Sternberg cells. 21, 22 In the present study, we evaluated for the first time multiple morphometric microvascular characteristics, in addition to microvessel density (MVD), in a large series of homogeneously treated patients with HL, relating them to several clinical, laboratory and pathologic parameters as well as to clinical outcome.
Patients and methods

Patients
We retrospectively analyzed 286 consecutive, nonpediatric, HIV-negative patients with histologically proven HL, for whom paraffin-embedded lymph node tissue at diagnosis was available. All patients had been diagnosed, treated and followed-up at the Hematology Section, First Department of National and Kapodistrian University of Athens, at Laikon General Hospital between 1988 and 2003. Their clinical, pathologic and laboratory features at presentation are given in Table 1 . Clinical staging was performed according to the Ann-Arbor system using standard procedures. Age was categorized as o35, 35-44 and X45 years, while the number of involved anatomic sites as 1, 2, 3 and X4. Anemia was defined as the presence of Hb levels o13 g/dl for males and o11.5 g/dl for females and the cutoff for ESR was 50 mm the 1st hour, for WBC 15 Â 10 9 /l, for lymphocyte count 1.0 Â 10 9 /l, for albumin levels 4 g/dl and for IPS 3. 4, 23, 24 LDH levels were analyzed as normal vs abnormal. Treatment consisted of antracycline-based chemotherapy with or without radiotherapy in 271 patients. The remaining 15 patients had been treated with MOPP or its variant ChlVPP (n ¼ 13) or radiotherapy alone (n ¼ 2). The median follow-up for all 286 patients was 57.7 months (range 5-213).
All tissue samples were pretreatment lymph node biopsies, fixed in 10% buffered formalin solution and embedded in paraffin. All cases were reviewed by three hematopathologists independently and classified according to the WHO classification.
Immunohistochemistry for CD34
A total of 4 mm sections of each sample were processed for immunohistochemical identification of microvascular endothelial cells with a mouse monoclonal antibody against CD34 (Clone HPCA-1; Becton Dickinson, San Jose, CA, USA). The antibody was applied at a dilution of 1 : 80 for 1 h. Before staining, slides were incubated four times for 5 min in citrate buffer pH 6.0, at 750 W, in a microwave oven. Application of the primary antibody was followed by the two-step horseradish peroxidase technique, using Dako Envision Kit (Dako, Carpinteria, CA, USA). All specimens were treated using identical procedures. Negative controls (ie sections in which the primary antibody was substituted with nonimmune mouse serum) were also stained in each run.
Microvessel counting and image analysis
The method has been described in detail previously. 8, 11 Briefly, immunohistochemically stained slides for CD34 were scanned, field per field, at Â 100 magnification, to identify the region showing the most intense vascularization ('hot spot') 7, 25 ( Figure 1 ). In cases including remnants of normal tissue (eg interfollicular HL), these areas were shielded to ensure that microvessel counting was performed in neoplastic tissue. 18 The magnification was then changed to Â 250 and the hot spot was photographed and printed on high-quality photographic paper, in order to improve resolution. Photographs were digitalized and stored as 24-bit BMP files. Any clearly stained endothelial cell or cluster was considered as a single countable microvessel, irrespective of the presence of a lumen. The outline of each microvessel was traced and the following morphometric parameters relating to microvessel caliber and shape were estimated: area, perimeter, major axis length, minor axis length and shape factor (4pn area/perimeter 2 ). 26 The variables entered into the statistical analysis were the total count of microvessels in the hot spot (MVD), the mean values of the above morphometric indices of the microvessels in the hot spot, total vascular area (TVA) and the number of vascular ramifications per 100 vessel sections (branching), as an expression of the complexity of the microvascular network. 27 The whole procedure took place by a single observer (NK) without any knowledge of the patients' clinical data.
Statistical analysis
To confirm that the above counting technique was representative of angiogenesis in the lymph nodes infiltrated by HL, we randomly selected 10 cases, in which the mean values of morphometric variables were counted in three random fields All variables were available in at least 280 patients except of lymphocyte counts (n ¼ 245), ESR (n ¼ 219), serum albumin (n ¼ 229) and serum LDH levels (n ¼ 216). All numbers represent percentages, unless otherwise specified.
Figure 1
Immunohistochemical staining of bone marrow endothelial cells for CD34 in two cases of HL displaying a rather small number of thin vessels (a) and a large number of round vessels of smaller caliber (b). The outline of each vessel is traced; the red layer represents the section area of each vessel. The perpendicular lines correspond to major and minor axis of each microvessel.
Â 250. The resulting figures closely correlated with those obtained in the hot spot (r ¼ 0.932). These 10 cases were also evaluated by a second observer (PK). Both interobserver and intraobserver variability was very low, with Spearman's correlation coefficients ranging from 0.851 to 0.928. The normality of distributions was tested with the KolmogorovSmirnov test. Logarithmic transformation of microvascular parameters except for branching was necessary to obtain normal distributions. Given that in most cases no arborizing microvessels were seen, branching was examined as a categorical variable. The relationship of microvascular parameters with clinicopathologic characteristics was tested with independent samples t-test, one-way analysis of variance (ANOVA) and Pearson's correlation coefficient, as appropriate.
Only patients treated homogenously with antracycline-based chemotherapy with or without radiotherapy (n ¼ 271) were included in survival analysis. Overall disease-specific survival (ODSS) was defined as the time from diagnosis to death of progressive disease or last follow-up. Failure-free survival (FFS) was defined as the time from diagnosis to failure of complete remission (CR) achievement requiring the switch to other chemotherapeutic regimen, documentation of relapse or last follow-up. One patient with toxic death during primary treatment and five patients dying of second malignancy while being in first CR were censored at the time of death in both FFS and ODSS analysis. At the time of the present analysis, 50 failures and 22 deaths of disease had been recorded. Actuarial survival curves were plotted according to Kaplan-Meier method and compared with the log-rank test. Clinical and laboratory parameters were categorized, as stated in 'Patients' section. Microvascular parameters were categorized on the basis of the median value (shape factor, major and minor axis length, perimeter, area) or the median value rounded at its nearest 15% (MVD and TVA).
Multivariate analysis was performed using the stepwise Cox's regression model (forward selection strategy), with entry and removal criteria set up at P ¼ 0.05 and 0.10, respectively. Given that there were strong interrelations among microvessel caliber parameters (area, major axis length, minor axis length, perimeter) as well as between TVA and MVD, the above six microvascular parameters were subjected to factor analysis using the principal component extraction method. Each of the microvascular parameters was assigned to the factor with which it had the highest correlation. Multivariate analysis included the estimated factor scores (instead of the original six microvascular parameters) along with the remaining variables, shape factor and branching. In order to avoid any 'data-driven' categorization, numerical variables, excluding microvascular parameters, were used in continuous form in multivariate analysis.
Results
Microvascular parameters and clinicopathologic characteristics
An increase of microvessel caliber was noted with increasing stage, as evidenced by higher values of area (P ¼ 0.002), perimeter (P ¼ 0.007), major axis length (P ¼ 0.006) and minor axis length (P ¼ 0.017) in stages III and IV as opposed to stages I and II (t-test) ( Table 2) . On the contrary, MVD values were highest in stage I and gradually declined through stage II to stages III and IV (P ¼ 0.008, one-way ANOVA) (Table 2, Figure 2) . A similar decrease of MVD was also recorded with increasing number of involved anatomic sites (P ¼ 0.003, oneway ANOVA).
Positive correlations emerged between age on the one hand and MVD (r ¼ 0.125, P ¼ 0.035) or TVA (r ¼ 0.129, P ¼ 0.030) on the other. In addition, MVD decreased with increasing LDH ratio (r ¼ À0.149, P ¼ 0.029). 
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None of the microvascular parameters was associated with lymph node histology, bone marrow involvement or the remaining clinical and laboratory characteristics of the patients (for all P40.10).
Correlations among the various morphometric variables
Strong positive correlations existed among vessel caliber microvascular parameters (area, major and minor axis length, perimeter) and TVA, the correlation coefficient ranging from 0.268 to 0.846 (Po0.001). Likewise, MVD strongly correlated with TVA (r ¼ 0.732, Po0.001). A loose negative correlation also emerged between shape factor and vessel caliber parameters, with correlation coefficients ranging from À0.119 to À0.360 (Po0.001 to P ¼ 0.044).
Prognostic relevance of morphometric variables
Univariate analysis disclosed that FFS was adversely affected by low values of shape factor (P ¼ 0.006) (Figure 3 ). When patients were stratified by stage, the statistical significance of shape factor remained for early (I-II) stages (P ¼ 0.044) but became marginal (P ¼ 0.075) for advanced (III-IV) stages. Several established conventional factors significantly predicted for inferior FFS, as expected (Table 3) . Using factor analysis, as described in 'Patients and methods' section, only two factors could be extracted. Factor 1 represented the vessel caliber, relating to area, minor axis length, major axis length and perimeter, whereas factor 2 represented the extent of microvascular network, relating to MVD and TVA. When the two factor scores, branching, shape factor and the clinicopathologic characteristics of the patients were entered into multivariate analysis, FFS was independently linked to shape factor and albumin levels (Table 4 , model 1). Should multivariate analysis be performed without taking into account serum albumin levels due to a high rate of missing values (Table 1) , shape factor Figure 3 Failure-free survival is adversely affected by low values of shape factor. The 5-year failure-free survival rate is 71% for the group below the median (0.62) and 88% for the group above the median (Kaplan-Meier curves). The MVD/TVA factor reflects the extent of angiogenesis.
Angiogenesis in Hodgkin's lymphoma P Korkolopoulou et al emerged again as an independent factor affecting FFS along with the number of involved anatomic sites (Table 4 , model 2). With regard to ODSS, established conventional factors were also significant in univariate analysis, as expected (Table 3) . Among microvascular parameters only MVD437 (P ¼ 0.040) and TVA 428 000 mm 2 (P ¼ 0.046) reached statistical significance (Figure 4) . When patients were stratified by stage, the significance of MVD remained for advanced stages (P ¼ 0.050), but that of TVA disappeared. Multivariate analysis resulted in a three-parameter model consisting of factor 2 score (MVD/TVA, corresponding to the extent of angiogenesis), the age of the patient and the number of involved anatomic sites (Table 4) .
Discussion
The identification of biologically sensible prognostic factors in HL has been recently a subject of intense scrutiny. 28 Tumor angiogenesis, especially microvessel counts, has attracted growing attention as a prognostic factor in solid tumors. The quantification of the neovascular response elicited within and around a tumor might provide an estimate of the angiogenic capacity of tumor cells and, hence, might facilitate the assessment of the likelihood of invasion and metastasis in individual cases. 29 Whether this concept also applies to malignant lymphomas remains an open question.
The present investigation demonstrates a gradual increase in microvessel caliber in parallel with advancing disease stage, lending support to the notion that the larger the lumen of microvessels the higher the chance of neoplastic cells to have access into the circulation, spreading and colonizing target organs. 27 On the contrary, MVD declined with stage progression and increasing number of involved anatomic sites. Though paradoxical this finding may sound, it is not without precedence, having been recorded in colorectal carcinoma 27 and lobular breast carcinoma. 30 In experimental tumor models, the progression of neoplastic disease is similarly accompanied by an inhibition of the rate of new vessel formation. 31 This phenomenon may reflect the influence of antiangiogenic factors, 32 the inadequacy of the angiogenic mechanisms to support the viability of a growing neoplasm, or a gradual restriction of the neoplastic cells' metabolic demands. 27 Experimental and histologic data suggest that angiogenesis may be induced as early as during the transition of hyperplasia to neoplasia. 33, 34 It might be hypothesized that the disparity between the changes of MVD and microvessel caliber parameters with advancing disease stages stems from the prevalence of vessel differentiating factors, such as angiopoietin 1 and 2 and metalloproteinases, upon vascular growth factors, as VEGF, bFGF and hepatocyte growth factor. 35 Irrespective of the underlying mechanisms, our findings are consistent with the hypothesis that the acquisition of an angiogenic phenotype is an early event in the progression of HL and that the angiogenic capacity of neoplastic cells is tempered thereafter unable to keep pace with tumoral growth. 27 In this regard, HL differs from B chronic lymphocytic leukemia, in which the promotion of angiogenesis parallels the progression in clinical stage. 9 Ultrastructural studies have demonstrated that NHL display complex vascular structures and endothelial sprouts as a result of vivid vasoproliferation in advanced stages. 16 HL differs in this regard, since there appears to be no relationship between the complexity or the shape of microvessels and stage, raising the hypothesis that microenvironment exerts distinct influence on vascular response in these two hematopoietic neoplasms.
The mechanisms conducting angiogenesis in HL remain to be elucidated. A recent report has shed light upon this issue demonstrating that both neoplastic cells and macrophages are capable of expressing VEGF in HL. 22 The absence of a significant relationship, however, between VEGF expression and MVD in the same study 22, 36 implies that VEGF might not be the only factor regulating angiogenesis in HL, other inhibitory and stimulatory molecules being probably important in this regard, as for example thymidine phosphorylase, thrombospondin or TGF-beta produced by the neoplastic or reactive cells. 37 Several features have been proposed to predict an inferior FFS and overall survival in HL, including both conventional clinical and laboratory characteristics and biological factors. 4, 23, 24, 28 In general, no meaningful and consistent relationship was found between microvascular characteristics and conventional factors, except of stage and age. This observation potentiates the concept that the prognostic significance of microvascular parameters is independent from conventional ones. Our results recapitulate most of the conventional prognostic factors, advocating that our cohort was representative and that survival Overall disese-specific survival is adversely affected by elevated MVD and TVA values. The 5-year survival rate is 87% for the group with MVD above 37 and 94% for the group with MVD below 37. The respective figures for TVA above and below 28 000 mm 2 are 86 and 95%. The cutoffs were selected on the basis of the median value (see 'Statistical analysis').
analysis was valid. To the best of our knowledge, the present study is the first to deal with the impact of angiogenesis on the outcome of a large number of homogeneously treated patients with HL.
The lower survival probability assigned to those cases with increased values of MVD and TVA in univariate analysis and to angiogenesis factor 2 (reflecting the extent of angiogenesis) in multivariate analysis is largely reflective of the improved perfusion of the lymph node, alleviating growth restriction imposed on neoplastic cells because of their dependence on nutrient delivery and catabolite removal by diffusion. 38 Proliferating blood vessels are also more vulnerable to penetration by tumor cells compared to mature vessels, because they have leaky and weak basement membranes. 38 Given these data, it follows that the larger the vascular surface area the higher the chance for tumor cells to enter the systemic circulation. Alternatively, the adverse effect of increased vessel density and TVA may portray a sequence of events analogous to that in solid tumor angiogenesis: aggressive rapidly growing neoplastic cells soon lead their environment to hypoxia, which, being an important stimulus for the production of angiogenic factors, will result in excessive angiogenesis. 39 The shape of the microvessels has rarely been dealt with in angiogenesis studies. The presence of flattened vessel sections, evidenced as low values of shape factor, implied a lesser FFS probability. More importantly, once shape factor was entered into Cox's model, it replaced other established prognostic factors, so that the final model included only shape factor and albumin levels or -alternatively -the number of involved anatomic sites. This particular shape of microvessels denotes a decrease in intraluminal pressure according to Bernulli's law, resulting in excess blood flow. Following this line of argument, it could be hypothesized that those patients, whose lymph nodes present a large number of flattened microvessels are endowed with a nutritional advantage, allowing the earlier relapse of their disease or facilitating treatment failure. The permissive role of the low values of shape factor in terms of disease progression has also been recorded in myelodysplastic syndromes.
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In summary, the present study provides evidence that the maximum level of microvessel formation coincides with the early stages of HL and that progression in stage is accompanied by qualitative, rather than quantitative, alterations in microvascular network. More importantly, the assessment of microvascular network provides independent prognostic information in HL, requiring the concomitant evaluation of the vascular density and the size and shape of the microvessels. Prospective validation of our observations is warranted, before prognostic models incorporating microvascular parameters along with conventional prognostic factors can be built up. This also applies to the potential value of antiangiogenic therapy as an adjunct to the currently available treatment options.
